Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

Open access

Abstract

The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic allergen administrations increased tolerance to nasal provocation with pollen already within 4 months ( P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard s.c. immunotherapy ( P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay fever symptoms ( P < 0.001), reduced skin prick test reactivity ( P < 0.001), decreased specific serum IgE ( P < 0.001), caused fewer adverse events than s.c. immunotherapy ( P = 0.001), enhanced compliance ( P < 0.001), and was less painful than venous puncture ( P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.0803725105

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Epidemiology Surveys and Danske Equities (ALK-Abelló, Hørsholm, Denmark, 2005).

Cited by

See all 364

Metadata

Authors
Senti, G., Prinz Vavricka, B. M., Erdmann, I., Diaz, M. I., Markus, R., McCormack, S. J., Simard, J. J., Wüthrich, B., Crameri, R., Graf, N., Johansen, P., & Kündig, T. M.
Affiliations
  • University Hospital Zurich (CH)
  • Unit for Experimental Immunotherapy, Department of Dermatology, and
  • MannKind Corporation (United States) (US)
  • Swiss Institute for Asthma and Allergy Research, 7270 Davos, Switzerland
Venue
Proceedings of the National Academy of Sciences
Published
2008-11-18
Volume
105
Issue
46
Pages
17908-17912
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1975755712
Cited by
364
References
26
Citations by year
2026: 8 · 2025: 11 · 2024: 14 · 2023: 22 · 2022: 26 · 2021: 18 · 2020: 21 · 2019: 12 · 2018: 18 · 2017: 23 · 2016: 24 · 2015: 19 · 2014: 35 · 2013: 30 · 2012: 26
FWCI
12.08
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (114634, 310000)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
allergen immunotherapy, subcutaneous immunotherapy, grass pollen allergy, rhinoconjunctivitis, allergic rhinitis, IgE-mediated allergy, lymph node injection, treatment duration, treatment safety, medication adherence
MeSH terms
Adolescent, Adult, Aged, Allergens, Desensitization, Immunologic, Female, Humans, Hypersensitivity, Immunoglobulin E, Immune Tolerance, Injections, Intralymphatic, Injections, Subcutaneous, Male, Middle Aged, Pain, Skin Tests, Time Factors, Treatment Outcome, Anti-Allergic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.